2022
Healiva® acquisisce da Smith+Nephew due asset di terapia cellulare per la guarigione delle ferite
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn to present data at upcoming AMMF’s 2022 European Cholangiocarcinoma Conference
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®
United States Ambassador Scott Miller meets the Chairman of Farma Industria Ticino Association
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
![](https://www.farmaindustriaticino.ch/files/2015/05/logo_zambon-160x160.png)
Linkedin